1 – 10 of 17
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The need for core outcome sets in renal cancer clinical effectiveness research
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer
(
- Contribution to journal › Scientific review
-
Mark
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making : Proposal from the European Association of Urology Guidelines Panel
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022 : The Urologist's Point of View
(
- Contribution to journal › Debate/Note/Editorial
- 2022
-
Mark
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
European Association of Urology Guidelines on Renal Cell Carcinoma : The 2022 Update
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibitor–based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care
(
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses : A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel
(
- Contribution to journal › Article